Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor

Journal of Emergency Medicine

Volumn 52, Issue 2, 2017, Pages 223-226

  Andrews, Tory J ^a   Cox, Robert D ^a,b   Parker, Christina ^a,b   Kolb, James ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Mississippi Poison Control Center   (United States)

Author keywords

acetone; canagliflozin; euglycemic diabetic ketoacidosis; SGLT2; sodium glucose cotransporter 2 inhibitors

Indexed keywords

ACETONE; ACETYLSALICYLIC ACID; ALBUMIN; ASCORBIC ACID; ATORVASTATIN; BUDESONIDE PLUS FORMOTEROL; CANAGLIFLOZIN PLUS METFORMIN; CYANOCOBALAMIN; GLUCOSE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; INSULIN; INSULIN GLARGINE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; KETONE; LEVOTHYROXINE SODIUM; MAGNESIUM OXIDE; METFORMIN; PANTOPRAZOLE; PRAMIPEXOLE; TRAZODONE; VITAMIN D; VORTIOXETINE; ANTIHYPERTENSIVE AGENT; CANAGLIFLOZIN; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ALKALOSIS; ARTERIAL GAS; ARTICLE; CARBON DIOXIDE TENSION; CASE REPORT; CONFUSION; DIABETIC KETOACIDOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HEART ATRIUM ENLARGEMENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INSULIN INFUSION; INSULIN TREATMENT; LUNG EDEMA; MENTAL HEALTH; METERED DOSE INHALER; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN TENSION; PH; PRIORITY JOURNAL; SINUS TACHYCARDIA; UNSPECIFIED SIDE EFFECT; AGONISTS; ANALYSIS; BLOOD; DIABETIC COMPLICATION;

ACETONE; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES COMPLICATIONS; DIABETIC KETOACIDOSIS; FEMALE; HUMANS; INSULIN; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85000982091     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2016.07.082     Document Type: Article

References (15)

1. 1 Tahrani, A.A., Bailey, C.L., Del Prato, S., Barnett, A.H., Management of type 2 diabetes: new and future developments in treatment. Lancet 378 (2011), 182–197.
2. 2 U.S. Food and Drug Administration. Drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed December 4, 2015.
3. 3 Ogawa, W., Sakaguchi, K., Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Invest 7 (2016), 135–138.
4. 4 Peters, A.L., Buse, J.B., Diner, J.C., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
5. 5 Kitabchi, A.E., Umpierrez, G.E., Miles, J.M., Fisher, J.N., Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32 (2009), 1335–1343.
6. 6 Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
7. 7 Bonner, C., Kerr-Conte, J., Gmyr, V., et al. Inhibition of the glucose transporter with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21 (2015), 512–517.
8. 8 Taylor, S.I., Blau, J.E., Rother, K.I., SGL2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100 (2015), 2849–2852.
9. 9 Whittington, J.E., La'ulu, S.L., Hunsaker, J.J.H., Roberts, W.L., The osmolal gap: what has changed?. Clin Chem 56 (2010), 1353–1355.
10. 10 Hoffman, R.S., Smilkstein, M.J., Rowland, M.A., Goldfrank, L.R., Osmol gaps revisited: normal values and limitations. J Toxicol Clin Toxicol 31 (1993), 81–93.
11. 11 Slaughter, R.J., Mason, R.W., Beasley, D.M.G., Vale, J.A., Schep, L.J., Isopropanol poisoning. Clin Toxicol 52 (2014), 470–478.
12. 12 Sulway, M.J., Malins, J.M., Acetone in diabetic ketoacidosis. Lancet 2 (1970), 736–740.
13. 13 Monaghan, M.S., Olsen, K.M., Ackerman, B.H., Fuller, G.L., Porter, W.H., Pappas, A.A., Measurement of serum isopropanol and the acetone metabolite by proton nuclear magnetic resonance: application to pharmacokinetic evaluation in a simulated overdose model. Clin Toxicol 33 (1995), 141–149.
14. 14 Ramu, A., Rosenbaum, J., Blaschke, T.F., Disposition of acetone following acute acetone intoxication. West J Med 129 (1978), 429–432.
15. 15 Degroote, N.E., Pieper, B., Blood glucose monitoring at triage. J Emerg Nurs 19 (1993), 131–133.